SPRB - NASDAQ
Spruce Biosciences, Inc.
$53.16
+8.1%Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
At a Glance
Live Snapshotsprb
Selling, General and Administrative Expenses
Last Annual Value
16.99M
3-Year CAGR
12%
5-Year CAGR
25%
10-Year CAGR
27%
Spruce Biosciences, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. NASDAQ:SPRB | 16.99M | 10.3% | 8.4% | N/A | |
 OS Therapies Incorporated NYSE:OSTX | 3.97M | 52.5% | 21.5% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 15.85M | -5.3% | 1.4% | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 63.12M | 4.7% | -0.4% | 10.0% | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 23.85M | -5.7% | 0.4% | N/A | |
 Cibus, Inc. NASDAQ:CBUS | 26.91M | -2.4% | 11.8% | 15.0% | |
 ImageneBio Inc NASDAQ:IMA | 20.73M | -6.0% | 2.8% | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 15.39M | 106.1% | -20.7% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 8.72M | 2.3% | 8.0% | 13.5% | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | 47.22M | -6.6% | 11.4% | N/A | |
 Shattuck Labs, Inc. NASDAQ:STTK | 17.23M | -3.7% | -1.6% | N/A |
Spruce Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your SPRB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.